CAR-T cell therapy market: Size, Trends and Growth Analysis till 2027 – Credence Research

 Breaking News
  • No posts were found

CAR-T cell therapy market: Size, Trends and Growth Analysis till 2027 – Credence Research

CAR-T cell therapy market: Size, Trends and Growth Analysis till 2027 - Credence Research
The global CAR-T cell therapy market was valued at US$ 72.0 Mn in 2017 expanding at a CAGR of 51.1% from 2018 to 2026.

The global CAR-T cell therapy market was valued at US$ 72.0 Mn in 2017 expanding at a CAGR of 51.1% from 2018 to 2026.

Market Insights

The CAR-T cell therapy market is driven by factors such as rising prevalence of cancer, growing research in the immune-oncology, and massive funding from government health institution and pharma giants in CAR-T cell therapy development. The diagnosis of acute ALL is very ambiguous as the symptoms overlap with Non-Hodgkin lymphoma. World Health Organization guidelines have postulated that acute lymphocytic leukemia can be prevented up to a certain extent by prohibiting the exposure to radiation, chemical, viral infection, cigarette smoking and prolonged exposure to gasoline and electromagnetic fields. The traditional approach adopted for the treatment of leukemia was blood transfusion to increase the count of healthy blood cells, antibiotics used to curb the spread of infection and chemotherapy to kill the leukemia cells present in the bone marrow. However, advances in the cell therapy and gene therapy has have rendered the development of oncology treatment by body’s own immune system. The FDA approved CAR-T cell therapy are Axicabtagene ciloleucel (Yescarta) and Tisagenleucel (Kymriah),). Currently CD19 antigens have been approved by USFDA for the treatment of relapsed b-cell acute lymphocytic leukemia. Whereas, there are more than 2,000 candidates in the clinical trials for different cancer indications.  

Browse the full report CAR-T cell Therapy Market – Growth, Future Prospects, Competitive Analysis, 2018 – 2026 report at  https://www.credenceresearch.com/report/car-t-cell-therapy-market

CD19 antigens as CAR-T cell therapy for the treatment of B cell acute lymphocytic leukemia and increasing number of children suffering with acute lymphocytic leukemia is responsible for the dominance of ALL. Geographically, North America dominated the CAR-T cell therapy market due to approval of two CAR-T cell therapy candidates in the region. Moreover, rising prevalence of relapsed acute lymphocytic leukemia and technological advancement in the screening of cancer drives the CAR-T cells therapy market. Moreover, the domicile of pharmaceutical companies pioneering in CAR-T cell therapy further increases the dominance of United States. Increasing geriatric population suffering with leukemia and government initiatives to fight cancer will result in the growth of CAR-T cell therapy in Europe and Asia Pacific. However, penetration of CAR-T cell therapy within low and middle income economies are primarily hampered owing to the unavailability of suitable healthcare infrastructure and the lack of disposable income for such premium priced therapeutic options. The major pharmaceutical players actively engaged in the CAR-T cell therapy market are Gilead Sciences, Inc., Bellicum Pharmaceuticals, Inc., Immune Therapeutics, Celgene Corporation, Cellectis, Kite Pharma, Eureka Therapeutics, Juno Therapeutics, Sorrento Therapeutics and Novartis AG among others.

Increasing Adoption of CAR-T Cell Therapy in North America will Drive Swift Growth during the Forecast Period

In 2017, North America demonstrates supremacy in the global CAR-T cell therapy market owing to the exclusive availability of the two approved products Kymriah (Novartis AG) and Yescarta (Gilead Sciences, Inc.). Developed healthcare infrastructure, high accessibility to advanced therapies, rise in healthcare expenditure, incessant investment in R&D activities, and presence of established market leaders further catalyzes the overall market growth in this region. With Medicare constantly working on structuring suitable reimbursement policies for dynamically priced CAR-T cell therapies, the demand for it is projected to increase during the forecast period. In Asia Pacific, the market entry of Kymriah expected by end of 2018 in Japan. The extensive pipeline portfolio for CAR-T cell therapy in China and the continuous growing cancer prevalence in Asia Pacific regions predominantly contribute to the maximum growth.

Key Market Movements:
• Rising prevalence of patients suffering with relapsed b cell acute lymphocytic leukemia
• Proactive role adopted by regulatory agencies for the expedited approval of CAR T cell therapy
• Promising pipeline for CAR-T cell therapy focusing on CD22, CD30 antigens for the treatment of non-Hodgkin’s lymphoma and acute myeloid leukemia respectively
• Higher adoption of Immunotherapy for cancer treatment in North America and Europe contribute towards the growth of the market
• Partnerships, collaboration and capital funding between pharmaceutical giants and budding biotechnology to increase research and development of immunotherapy for cancer treatment

Key questions answered in this report

  • How the global CAR-T cell therapy market will perform during the forecast period from 2018 to 2026?
  • What are the latest trends in the CAR-T cell therapy market and valuable opportunities for key players?
  • Who are the leading players in the global CAR-T cell therapy market?
  • Which is the leading/and fastest region in the global CAR-T cell therapy market?
  • Currently, what are the reimbursement scenario and regulatory structure for the CAR-T cell therapy?
  • What are drivers and restrains governing the global CAR-T cell therapy market?
  • What is the pipeline scenario of the global CAR-T cell therapy market?
  • Which indications are being targeted using CAR-T cell therapy?
  • What is the status of the clinical trials studied for various antigens? 

Browse the full report CAR-T cell Therapy Market – Growth, Future Prospects, Competitive Analysis, 2018 – 2026 report at  https://www.credenceresearch.com/report/car-t-cell-therapy-market

Table of content:

Chapter 1 Preface
1.1 Report Description
1.1.1 Study Purpose
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Global CAR-T Cell Therapy Market Portraiture
2.2 Global CAR-T Cell Therapy Market, by Indication, 2017 vs 2026 (Value %)
2.3 Global CAR-T Cell Therapy Market, by Geography, 2017 vs 2026 (Value %)

Chapter 3 Global CAR-T Cell Therapy Market: Dynamics and Future Outlook
3.1 Overview
3.2 Market Drivers
3.2.1 Emerging Immuno-Oncology in Clinical Cancer Research
3.2.2 Rising Prevalence of Cancer
3.3 Challenges
3.3.1 High Cost of CAR-T Cell Therapy
3.4 Opportunities
3.4.1 Mergers and Acquisition in the CAR-T Cell Therapy Market
3.4.2 CAR-T Cell Therapy Beyond Cancer Treatment
3.5 Attractive Investment Proposition: Global CAR-T Cell Therapy Market, by Indication, 2018
3.6 Competitive Analysis: Global CAR-T Cell Therapy Market, 2017

Chapter 4 Global CAR T Cell Therapy Market, by Targeted Antigen, 2017-2026 (US$ Mn)
4.1 Overview
4.1.1 Global CAR T Cell Therapy Market, by Targeted Antigen, 2017 – 2026 (US$ Mn)
4.1.2 CD 19
4.2 Pipeline Therapy Analysis
4.2.1 CD 20
4.2.2 CD 22
4.2.3 CD 30
4.2.4 CD 33
4.2.5 GD 2
4.2.6 HER 2
4.2.7 MESO
4.2.8 EGFRvIII
4.2.9 Major Clinical-stage CAR-T projects with commercial licensees

Chapter 5 Global CAR T Cell Therapy Market, by Indication, 2017-2026 (US$ Mn)
5.1 Overview
5.2 Non-Hodgkin’s Lymphoma
5.3 Acute Lymphocytic Leukemia
5.4 Chronic Lymphocytic Leukemia

Chapter 6 Global CAR-T cell Therapy Market, by Geography, 2017 – 2026 (US$ Mn)
6.1 Overview
6.1.1 Global CAR-T cell Therapy Market, by Geography, 2017 – 2026 (US$ Mn)
6.2 North America
6.2.1 North America CAR-T cell Therapy Market, by Indication, 2017 – 2026 (US$ Mn)
6.2.2 North America CAR-T cell Therapy Market, by Country, 2017 – 2026 (US$ Mn)
6.2.2.1 U.S. CAR-T cell Therapy Market, 2017 – 2026 (US$ Mn)
6.2.2.2 Canada CAR-T cell Therapy Market
6.3 Europe
6.3.1 Europe CAR-T cell Therapy Market, by Indication, 2017 – 2026 (US$ Mn)
6.3.2 Europe CAR-T cell Therapy Market, by Country/Region, 2017 – 2026 (US$ Mn)
6.3.2.1 United Kingdom CAR-T cell Therapy Market
6.3.2.2 Germany CAR-T cell Therapy Market
6.3.2.3 Rest of Europe CAR-T cell Therapy Market
6.4 Asia Pacific
6.4.1 Asia Pacific CAR-T cell Therapy Market, by Indication, 2017 – 2026 (US$ Mn)
6.4.2 Asia Pacific CAR-T cell Therapy Market, by Country/Region, 2017 – 2026 (US$ Mn)
6.4.2.1 Japan CAR-T cell Therapy Market
6.4.2.2 China CAR-T cell Therapy Market
6.4.2.3 Rest of Asia Pacific CAR-T cell Therapy Market
6.5 Rest of World
6.5.1 Latin America
6.5.2 Latin America CAR-T cell Therapy Market, by Indication, 2017 – 2026 (US$ Mn)
6.5.2.1 Mexico CAR-T cell Therapy Market
6.5.2.2 Brazil CAR-T cell Therapy Market
6.5.2.3 Rest of Latin America CAR-T cell Therapy Market
6.5.3 Middle East & Africa
6.5.4 Middle East & Africa CAR-T cell Therapy Market, by Indication, 2017 – 2026 (US$ Mn)

Chapter 7 Company Profiles
7.1 Bellicum Pharmaceuticals, Inc.
7.2 Celgene Corporation
7.3 Cellectis
7.4 Eureka Therapeutics, Inc.
7.5 Immune Therapeutics, Inc.
7.6 Gilead Sciences, Inc.
7.7 Novartis AG
7.8 Sorrento Therapeutics, Inc.

Browse the full report CAR-T cell Therapy Market – Growth, Future Prospects, Competitive Analysis, 2018 – 2026 report at  https://www.credenceresearch.com/report/car-t-cell-therapy-market

Realated Reports:

Hypoactive Sexual Desire Disorder (HSDD) Treatment Market By Therapy (Buspirone, Bupropion, Testosterone, Flibanserin, Bremelanotide, Cognitive Behavior Therapy) – Growth, Future Prospects & Competitive Analysis, 2019 – 2027

Media Contact
Company Name: Credence Research
Contact Person: Chris Smith
Email: Send Email
Phone: 18003618290
City: SAN JOSE
State: CA
Country: United States
Website: https://www.credenceresearch.com/report/car-t-cell-therapy-market


Warning: count(): Parameter must be an array or an object that implements Countable in /home/atlantanewsonlin/public_html/news.augustaheadlines.com/wp-content/themes/legatus-theme/includes/single/post-tags.php on line 5
Share

Categories